By Industry Standard Research
There is currently a lot of talk about how artificial intelligence (AI) may be able to reduce the burden of case processing while improving compliance and reducing processing costs. We asked 100 decision-makers in the pharmacovigilance space where in the adoption curve of new technologies they see their organizations with respect to AI in pharmacovigilance. Over half of the respondents consider their companies to be at least in the early majority with respect to adopting the use of AI in pharmacovigilance.
“What innovative processes / solutions is your company doing or planning to do to make pharmacovigilance work less manual?” (n=100)
“Thinking of the company you work for, where in the adoption curve of new technologies do you see the organization with respect to AI in pharmacovigilance?” (n=100)